Lumito's CEO Mattias Lundin presented the company and the upcoming product launch to the public in the well-attended Auditorium at Medicon Village in Lund.
After the presentation, there was opportunity for Q&As which included delayed launch, possibilities for multiplexing and analysis of more biomarkers as well as whether there are plans to launch the product in developing countries in the future. If you weren't in Lund, you have the opportunity to watch the presentation here: https://youtu.be/v6fe3g9zKyQ.
The presentation is also available on Lumito's website.
For further information, please contact:
Lumitos CEO, Mattias Lundin
e-mail: ml@lumito.se
Ph: +46768684509
Lumito specializes in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalized healthcare. The technology enables higher contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has chosen to focus primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off from a research group at the Department of Atomic Physics and Laser Centre. www.lumito.se/en
The share is traded on NGM Nordic SME, under the name LUMITO and Mentor is Mangold Fondkommission, phone: 08-503 015 50.
